|View printer-friendly version|
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
“SB 9200 is a novel and exciting potential oral therapy with promising antiviral activity, and we are excited to see Professors Yuen and Locarnini, leaders in the field of clinical Hepatology and Virology, present data at this prestigious conference from the first low dose cohort of the ACHIEVE trial showing promising results of SB 9200 in patients with hepatitis B,” said
The annual AASLD conference will highlight the latest liver diseases research and discuss treatment outcomes with physicians, researchers and healthcare practitioners involved in the science and practice of hepatology. The abstracts will be presented at the conference as follows:
Source: Spring Bank Pharmaceuticals Inc.